RECOMBINANT IL-2 AND B-INTERFERON IN LYMPHOMA

研究目标包括测定IL-2和b-干扰素的疗效。 IL-2，以及评估复发或复发患者的毒性 难治性非霍奇金淋巴瘤。假设有可能存在 抗病毒、抗增殖和免疫调节的协同作用 IL-2和b-干扰素有待进一步研究。IL-2单独和联合应用的影响 联合b-干扰素体内激活NK和LAK细胞将 接受评估和NK和活化与肿瘤的r反应治疗将 相互关联。

The study objectives include determining the efficacy of IL-2 and b-IFN + IL-2, as well as evaluating toxicity for patients with relapsed or refractory non-Hodgkin's Lymphoma. The hypothesis that there may be antiviral, antiproliferative, and immuno-modulating synergism between IL-2 and b-IFN will be uder investigation. The effect of IL-2 alone and in combination with b-IFN on in-vivo activation of NK and LAK cells will be assessed and NK and activation with tumor rresponse to therapy will be correlated.